Imugene Limited (AU:IMU) has released an update.
Imugene Limited has initiated the first patient dosing in the intravenous combination arm of its Phase 1 onCARlytics clinical trial, targeting advanced solid cancers with a novel CD19-expressing oncolytic virus paired with an existing CD19-targeting drug. This innovative approach aims to transform ‘targetless’ solid tumors into treatable targets using approved blood cancer therapies, potentially impacting 90% of the cancer market. Early results from the trial, which is being conducted at multiple U.S. sites, are anticipated by the end of 2024.
For further insights into AU:IMU stock, check out TipRanks’ Stock Analysis page.
